Your browser doesn't support javascript.
loading
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia, Tao; Li, Keyu; Niu, Nan; Shao, Yingkuan; Ding, Ding; Thomas, Dwayne L; Jing, Hao; Fujiwara, Kenji; Hu, Haijie; Osipov, Arsen; Yuan, Chunhui; Wolfgang, Christopher L; Thompson, Elizabeth D; Anders, Robert A; He, Jin; Mou, Yiping; Murphy, Adrian G; Zheng, Lei.
Afiliação
  • Xia T; Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 351, Baltimore, MD, 21231, USA.
  • Li K; The Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Niu N; The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Shao Y; Department of Gastrointestinal and Pancreatic Surgery, Department of General Surgery, and Cancer Center, The Zhejiang Provincial People's Hospital and the Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China.
  • Ding D; Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 351, Baltimore, MD, 21231, USA.
  • Thomas DL; The Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Jing H; The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Fujiwara K; Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Hu H; Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 351, Baltimore, MD, 21231, USA.
  • Osipov A; The Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Yuan C; The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wolfgang CL; Department of Gastrointestinal and Pancreatic Surgery, Department of General Surgery, and Cancer Center, The Zhejiang Provincial People's Hospital and the Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China.
  • Thompson ED; Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 351, Baltimore, MD, 21231, USA.
  • Anders RA; The Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • He J; The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Mou Y; The Zhejiang University Second Affiliated Hospital, Hangzhou, China.
  • Murphy AG; Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 351, Baltimore, MD, 21231, USA.
  • Zheng L; The Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Hematol Oncol ; 15(1): 37, 2022 03 28.
Article em En | MEDLINE | ID: mdl-35346322
ABSTRACT

BACKGROUND:

Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood.

METHODS:

For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data.

RESULTS:

This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B+CD8+ effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1-EOMES-CD8+ effector T cells are associated with long-term survival. However, only the density of PD-1-EOMES-CD8+ T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1+ tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1+ M1 or M2, PD-L1- M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1- M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1+ tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion.

CONCLUSIONS:

This study suggests that the densities of Granzyme-B+CD8+ effector T cells and non-exhausted PD-1-EOMES-CD8+ T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1+ tumor-associated macrophages as the immunotherapy for cholangiocarcinoma.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article